NCT04170023View on ClinicalTrials.gov

Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 16, 2019

Primary Completion Date

April 27, 2023

Study Completion Date

March 20, 2024

Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
DRUG

ALXN2050

Oral FD inhibitor

Trial Locations (11)

1010

Research Site, Grafton

8011

Research Site, Christchurch

34093

Research Site, Istanbul

35100

Research Site, Izmir

50134

Research Site, Florence

83100

Research Site, Avellino

M5G2C4

Research Site, Toronto

G6V 3Z1

Research Site, Lévis

06591

Research Site, Seoul

02006

Research Site, Albacete

SE5 9RS

Research Site, London

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY